Investigational drug · Phase 3
INS1009
Also called: Treprostinil Palmitil
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
5 still active
All registered trials
12
Any phase or sponsor naming "INS1009"
First trial start
2022
Aug 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INS1009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Interstitial Lung Disease
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Progressive Pulmonary Fibrosis
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "INS1009" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07805785 · 800 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 31, 2030
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: DuBois, Pennsylvania
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07481981 · 344 participants (planned) · Start Jul 21, 2026 · Primary completion Dec 28, 2028
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Arterial Hypertension
Sites: Los Angeles, California; Santa Barbara, California; Torrance, California · 39 sites in all
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07234032 · 344 participants (planned) · Start Jul 20, 2026 · Primary completion Jan 22, 2031
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Naples, Florida; Bend, Oregon; Prague, Czechia · 12 sites in all
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07179380 · 344 participants (planned) · Start Jan 7, 2026 · Primary completion Dec 30, 2028
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 186 sites in all
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPivotal-lookingCompleted
Insmed IncorporatedIndustry
NCT05147805 · 102 participants · Start Aug 24, 2022 · Primary completion Mar 27, 2025
Drug: Treprostinil Palmitil; Placebo · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 92 sites in all
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Pivotal-lookingActive, not recruiting
Insmed IncorporatedIndustry
NCT05649748 · 91 participants · Start Mar 7, 2023 · Primary completion Dec 31, 2026
Drug: Treprostinil Palmitil; Placebo · For: Pulmonary Arterial Hypertension
Sites: Jacksonville, Florida; Tampa, Florida; Chicago, Illinois · 45 sites in all
Insmed IncorporatedIndustry
NCT07102316 · 42 participants · Start Aug 19, 2025 · Primary completion Oct 25, 2025
Drug: TPIP F2; TPIP F3 · For: Healthy Volunteers
Sites: Salt Lake City, Utah
Insmed IncorporatedIndustry
NCT06091579 · 42 participants · Start Sep 17, 2020 · Primary completion Jan 12, 2021
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Healthy Volunteers
Sites: Austin, Texas
Insmed IncorporatedIndustry
NCT05176951 · 39 participants · Start Dec 22, 2022 · Primary completion Mar 14, 2024
Drug: Treprostinil Palmitil; Placebo · For: Pulmonary Hypertension
Sites: Barracas, Argentina; Rosario, Argentina; Buenos Aires, Argentina · 25 sites in all
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingCompleted
Insmed IncorporatedIndustry
NCT05649722 · 31 participants · Start May 11, 2023 · Primary completion Apr 1, 2026
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Autonomus City of Buenos Aires, Argentina; Rosario, Argentina; Macquarie Park, Australia · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease.
Church C, Molina-Molina M, Arias-Guillén M, et al. · Pulm Circ 2026
- Treprostinil palmitil inhalation powder leverages endogenous lung enzymes to provide sustained treprostinil.
Nguyen T, Chang C, Cipolla D, et al. · Expert Opin Drug Deliv 2024
- Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder.
Gauani H, Baker T, Li Z, et al. · Pharmaceutics 2023
- Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
Ismat FA, Usansky HH, Villa R, et al. · Adv Ther 2022
- Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
Corboz MR, Plaunt AJ, Malinin VS, et al. · J Pharmacol Exp Ther 2022
- Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
Corboz MR, Plaunt AJ, Malinin V, et al. · Eur J Pharmacol 2022
Also in development for Interstitial Lung Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- ATYR1923KRP-R120, EfzofitimodPhase 32 trials
aTyr Pharma, Inc. · Interstitial Lung Disease, Pulmonary Sarcoidosis
- MosliciguatPhase 32 trials
Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.